{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:29:59Z","timestamp":1789543799929,"version":"build-2803163510"},"reference-count":51,"publisher":"American Chemical Society (ACS)","issue":"6","license":[{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0802728"],"award-info":[{"award-number":["G0802728"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The opioids buprenorphine hydrochloride (BUP) and naltrexone hydrochloride (NTX) show promise as a combination treatment for addiction, but no means of delivering the two compounds in one medicine currently exist. In this paper, we report sufficient input rates of both these drugs from one iontophoretic transdermal drug delivery system. Experiments were performed using dermatomed pig skin mounted in glass side-bi-side cells. BUP and NTX were iontophoretically delivered together from the anode using direct constant current from Ag\/AgCl electrodes. The transdermal drug fluxes and the masses of drugs in both the stratum corneum and the underlying epidermis\/dermis were measured. The apparent electroosmotic flow was quantified using a neutral marker (acetaminophen). The effects of donor composition (drug concentration\/molar fraction and pH), current density and profile, and the choice of receptor solution were assessed. Iontophoresis dramatically increased the flux of both drugs compared to passive control values. Target fluxes (calculated from literature clearance values and required therapeutic plasma concentrations) were greatly exceeded for NTX and were met for BUP. The latter accumulated in the skin and suppressed electroosmotic flow, inhibiting both its own flux and that of NTX. NTX, in turn, negatively influenced the flux of BUP via co-ion competition. Lowering current density by increasing the delivery area resulted in increased electroosmotic flow but did not significantly affect current-normalized drug fluxes. Delivering the drugs from both electrodes and reversing the polarity for every 2 h did not increase the flux of either compound. In summary, during iontophoresis, BUP and NTX inhibited each other\u2019s flux by two distinct mechanisms. While the more complex behavior of BUP complicates the optimization of this drug combination, iontophoresis nevertheless appears to be a feasible approach for the controlled codelivery of NTX and BUP through the skin.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.9b00337","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T16:47:37Z","timestamp":1557420457000},"page":"2808-2816","source":"Crossref","is-referenced-by-count":22,"title":["Simultaneous Transdermal Delivery of Buprenorphine\nHydrochloride and Naltrexone Hydrochloride by Iontophoresis"],"prefix":"10.1021","volume":"16","author":[{"given":"Sarah F.","family":"Cordery","sequence":"first","affiliation":[{"name":"University of Bath , , ,","place":["Bath, U.K., BA2 7AY"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Husbands","sequence":"additional","affiliation":[{"name":"University of Bath , , ,","place":["Bath, U.K., BA2 7AY"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Bailey","sequence":"additional","affiliation":[{"name":"University of Bath , , ,","place":["Bath, U.K., BA2 7AY"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3227-9862","authenticated-orcid":true,"given":"Richard H.","family":"Guy","sequence":"additional","affiliation":[{"name":"University of Bath , , ,","place":["Bath, U.K., BA2 7AY"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2233-7654","authenticated-orcid":true,"given":"M. Begon\u0303a","family":"Delgado-Charro","sequence":"additional","affiliation":[{"name":"University of Bath , , ,","place":["Bath, U.K., BA2 7AY"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"2026090115413839000_cit1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/0269881106060835","article-title":"Naltrexone and buprenorphine combination\nin the treatment of opioid dependence","volume":"20","author":"Gerra","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"2026090115413839000_cit2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/adb.12020","article-title":"A non-rewarding,\nnon-aversive buprenorphine\/naltrexone\ncombination attenuates drug-primed reinstatement to cocaine and morphine\nin rats in a conditioned place preference paradigm","volume":"19","author":"Cordery","year":"2014","journal-title":"Addict. Biol."},{"key":"2026090115413839000_cit3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","article-title":"Buprenorphine","volume":"14","author":"Lewis","year":"1985","journal-title":"Drug Alcohol Depend."},{"key":"2026090115413839000_cit4","unstructured":"Lewis, J. W.; Lloyd-Jones, J. G.\n          Analgesic Compositions. U.S. Patent US46614921987."},{"key":"2026090115413839000_cit5","first-page":"161","article-title":"Overview of\nhuman pharmacokinetics of naltrexone","volume":"28","author":"Licko","year":"1981","journal-title":"Natl.\nInst. Drug Abuse Res. Monogr. Ser."},{"key":"2026090115413839000_cit6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0090-9556(25)06161-6","article-title":"Metabolism and disposition of naltrexone\nin man after oral and intravenous administration","volume":"9","author":"Wall","year":"1981","journal-title":"Drug Metab. Dispos."},{"key":"2026090115413839000_cit7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0090-9556(25)07782-7","article-title":"Naltrexone disposition\nin man after subcutaneous administration","volume":"12","author":"Wall","year":"1984","journal-title":"Drug\nMetab. Dispos."},{"key":"2026090115413839000_cit8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/clpt.1980.219","article-title":"Buprenorphine\nkinetics","volume":"28","author":"Bullingham","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026090115413839000_cit9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/jat\/20.6.369","article-title":"Human pharmacokinetics of intravenous, sublingual and buccal buprenorphine","volume":"20","author":"Kuhlman","year":"1996","journal-title":"J. Anal. Toxicol."},{"key":"2026090115413839000_cit10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/157015908784533842","article-title":"The effects of maternally\nadministered methadone, buprenorphine and naltrexone on offspring:\nReview of human and animal data","volume":"6","author":"Farid","year":"2008","journal-title":"Curr. Neuropharmacol."},{"key":"2026090115413839000_cit11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","article-title":"Relationship\nof plasma buprenorphine and norbuprenorphine to withdrawal symptoms\nduring dose induction, maintenance and withdrawal from sublingual\nbuprenorphine","volume":"93","author":"Kuhlman","year":"1998","journal-title":"Addiction"},{"key":"2026090115413839000_cit12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1360-0443.2006.01348.x","article-title":"An injection depot\nformulation of buprenorphine: extended biodelivery and effects","volume":"101","author":"Sigmon","year":"2006","journal-title":"Addiction"},{"key":"2026090115413839000_cit13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00213-008-1105-z","article-title":"Opioid\ndetoxification via single 7-day application of a buprenorphine transdermal\npatch: an open-label evaluation","volume":"198","author":"Lanier","year":"2008","journal-title":"Psychopharmacology."},{"key":"2026090115413839000_cit14","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/jps.20398","article-title":"Transdermal\ndelivery of naltrexone and its active metabolite 6-beta-naltrexol\nin human skin in vitro and guinea pigs in vivo","volume":"94","author":"Paudel","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"2026090115413839000_cit15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejps.2016.01.027","article-title":"Controlled transdermal\niontophoresis for poly-pharmacotherapy: Simultaneous delivery of granisetron,\nmetoclopramide and dexamethasone sodium phosphate in vitro and in\nvivo","volume":"85","author":"Ca\u0301zares-Delgadillo","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026090115413839000_cit16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1023\/A:1018985323001","article-title":"Determination of\nlidocaine concentrations\nin skin after transdermal iontophoresis - effects of vasoactive drugs","volume":"9","author":"Riviere","year":"1992","journal-title":"Pharm. Res."},{"key":"2026090115413839000_cit17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0378-5173(92)90003-K","article-title":"Effects of proteolytic-enzyme\ninhibitors of enhancement of transdermal iontophoretic delivery of\nvasopressin and an analog in rats","volume":"81","author":"Morimoto","year":"1992","journal-title":"Int. J. Pharm."},{"key":"2026090115413839000_cit18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.2042-7158.1992.tb03584.x","article-title":"Effect of\nproteolytic-enzyme inhibitors as absorption enhancers on the transdermal\niontophoretic delivery of calcitonin in rats","volume":"44","author":"Morimoto","year":"1992","journal-title":"J. Pharm. Pharmacol."},{"key":"2026090115413839000_cit19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/jps.2600761003","article-title":"Characterization\nof the permselective properties of\nexcised human skin during iontophoresis","volume":"76","author":"Burnette","year":"1987","journal-title":"J.\nPharm. Sci."},{"key":"2026090115413839000_cit20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0169-409X(92)90026-M","article-title":"Model systems in\niontophoresis transport efficacy","volume":"9","author":"Sage","year":"1992","journal-title":"Adv. Drug\nDelivery Rev."},{"key":"2026090115413839000_cit21","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1023\/A:1013318412527","article-title":"Contributions of\nelectromigration and electroosmosis to iontophoretic drug delivery","volume":"18","author":"Marro","year":"2001","journal-title":"Pharm. Res."},{"key":"2026090115413839000_cit22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/jps.20561","article-title":"Electromigration\nof ions across the\nskin: Determination and prediction of transport numbers","volume":"95","author":"Mudry","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"2026090115413839000_cit23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0168-3659(96)01354-5","article-title":"Iontophoretic\ndelivery of peptide drugs","volume":"41","author":"Green","year":"1996","journal-title":"J. Controlled Release"},{"key":"2026090115413839000_cit24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0168-3659(94)90249-6","article-title":"Iontophoretic enhancement\nof peptides - behavior of leuprolide versus model permeants","volume":"31","author":"Hoogstraate","year":"1994","journal-title":"J. Controlled Release"},{"key":"2026090115413839000_cit25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0378-5173(94)00323-W","article-title":"Iontophoretic delivery\nof nafarelin across the skin","volume":"117","author":"Delgado-Charro","year":"1995","journal-title":"Int. J. Pharm."},{"key":"2026090115413839000_cit26","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1023\/A:1012127512251","article-title":"Iontophoretic delivery\nacross the skin: Electroosmosis\nand its modulation by drug substances","volume":"14","author":"Hirvonen","year":"1997","journal-title":"Pharm.\nRes."},{"key":"2026090115413839000_cit27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0378-5173(86)90136-5","article-title":"Enhanced percutaneous absorption\nvia iontophoresis. 1. Evaluation of an in vitro system and transport\nof model compounds","volume":"30","author":"Bellantone","year":"1986","journal-title":"Int. J. Pharm."},{"key":"2026090115413839000_cit28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijpharm.2017.12.031","article-title":"Generic patches\ncontaining\nfentanyl: In vitro equivalence and abuse deterrent evaluation according\nto EMA and FDA guidelines","volume":"537","author":"Padula","year":"2018","journal-title":"Int. J. Pharm."},{"key":"2026090115413839000_cit29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0169-409X(92)90022-I","article-title":"Transdermal ion\nmigration","volume":"9","author":"Phipps","year":"1992","journal-title":"Adv.\nDrug Delivery Rev."},{"key":"2026090115413839000_cit30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0168-3659(00)00350-3","article-title":"Characterization\nof the iontophoretic\npermselectivity properties of human and pig skin","volume":"70","author":"Marro","year":"2001","journal-title":"J. Controlled Release"},{"key":"2026090115413839000_cit31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1023\/A:1018841111922","article-title":"Electrorepulsion\nversus electroosmosis: Effect of pH on the iontophoretic flux of 5-fluorouracil","volume":"16","author":"Merino","year":"1999","journal-title":"Pharm. Res."},{"key":"2026090115413839000_cit32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1023\/A:1011050829531","article-title":"Iontophoretic delivery of 5-aminolevulinic\nacid (ALA):\nEffect of pH","volume":"18","author":"Lopez","year":"2001","journal-title":"Pharm. Res."},{"key":"2026090115413839000_cit33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1196\/annals.1384.037","article-title":"Interpretation of oral fluid tests for drugs of abuse","volume":"1098","author":"Cone","year":"2007","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2026090115413839000_cit34","doi-asserted-by":"publisher","first-page":"R844","DOI":"10.1152\/ajpregu.00311.2009","article-title":"Passive diffusion\nof naltrexone into human and animal cells and upregulation","volume":"97","author":"Cheng","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2026090115413839000_cit35","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.2042-7158.1989.tb06495.x","article-title":"Iontophoretic\ntransport of weak electrolytes\nthrough the excised human stratum corneum","volume":"41","author":"Siddiqui","year":"1989","journal-title":"J.\nPharm. Pharmacol."},{"key":"2026090115413839000_cit36","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1023\/A:1013370529366","article-title":"Optimizing iontophoretic\ndrug delivery: Identification and distribution of the charge-carrying\nspecies","volume":"18","author":"Marro","year":"2001","journal-title":"Pharm. Res."},{"key":"2026090115413839000_cit37","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1529\/biophysj.105.074609","article-title":"Transport numbers in transdermal\niontophoresis","volume":"90","author":"Mudry","year":"2006","journal-title":"Biophys. J."},{"key":"2026090115413839000_cit38","unstructured":"Robson, D. L.\n          \n          Buprenorphine\nhydrochloride permeation through human skin in vitro; the effect of\nchemical enhancement and iontophoresis: effect of pH, distribution\nratio, penetration enhancers azone and oleyl alcohol, and iontophoresis\non the permeation of buprenorphine. Ph.D. Thesis, University of Bradford, 1988."},{"key":"2026090115413839000_cit39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0168-3659(96)01345-4","article-title":"Reverse iontophoresis - Parameters\ndetermining electro-osmotic\nflow. II. Electrode chamber formulation","volume":"42","author":"Santi","year":"1996","journal-title":"J.\nControlled Release"},{"key":"2026090115413839000_cit40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1023\/A:1011909623019","article-title":"Iontophoretic\npermselectivity of mammalian skin: Characterization of hairless mouse\nand porcine membrane models","volume":"15","author":"Luzardo-Alvarez","year":"1998","journal-title":"Pharm. Res."},{"key":"2026090115413839000_cit41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.2042-7158.1994.tb03891.x","article-title":"Human calcitonin delivery\nin rats\nby iontophoresis","volume":"46","author":"Thysman","year":"1994","journal-title":"J. Pharm. Pharmacol."},{"key":"2026090115413839000_cit42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2014.03.027","article-title":"Understanding the\npoor iontophoretic transport of lysozyme\nacross the skin: When high charge and high electrophoretic mobility\nare not enough","volume":"183","author":"Dubey","year":"2014","journal-title":"J. Controlled Release"},{"key":"2026090115413839000_cit43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jconrel.2005.12.020","article-title":"Prediction\nof iontophoretic transport\nacross the skin","volume":"111","author":"Mudry","year":"2006","journal-title":"J. Controlled Release"},{"key":"2026090115413839000_cit44","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1023\/A:1013322613436","article-title":"Iontophoretic delivery of ropinirole\nhydrochloride: Effect of current density and vehicle formulation","volume":"18","author":"Luzardo-Alvarez","year":"2001","journal-title":"Pharm. Res."},{"key":"2026090115413839000_cit45","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/jps.20348","article-title":"Effect of formulation\nfactors on electroosmotic glucose\ntransport through human skin in vivo","volume":"94","author":"Tamada","year":"2005","journal-title":"J. Pharm.\nSci."},{"key":"2026090115413839000_cit46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0169-409X(92)90027-N","article-title":"Skin biological\nissues in electrically enhanced transdermal delivery","volume":"9","author":"Ledger","year":"1992","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026090115413839000_cit47","unstructured":"Lopez-Castellano, A.; Guy, R. H.; Delgado-Charro, M. B. In  Effect of Area\non the Iontophoretic Transport of Phenylalanine and Propranolol across\nthe Skin, Proceedings of the International Symposium of Controlled\nRelease of Bioactive Materials, 1999; pp 405\u2013406."},{"key":"2026090115413839000_cit48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0168-3659(95)00015-Z","article-title":"Iontophoresis of\nnafarelin - effects of current density and concentration on electrotransport","volume":"35","author":"Delgado-Charro","year":"1995","journal-title":"J. Controlled Release"},{"key":"2026090115413839000_cit49","unstructured":"Lattin, G. A.; Spevak, R.\n          Iontophoretic\nDevice with Reversible Polarity. U.S. Patent US4406658A1983."},{"key":"2026090115413839000_cit50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0169-409X(92)90025-L","article-title":"Structure\ntransport relationships in transdermal iontophoresis","volume":"9","author":"Yoshida","year":"1992","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026090115413839000_cit51","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/add.13375","article-title":"Buprenorphine plus naloxone plus\nnaltrexone for the treatment of cocaine dependence: the Cocaine Use\nReduction with Buprenorphine (CURB) study","volume":"111","author":"Ling","year":"2016","journal-title":"Addiction"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.9b00337","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/16\/6\/2808\/67512419\/acs.molpharmaceut.9b00337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/16\/6\/2808\/67512419\/acs.molpharmaceut.9b00337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:41:44Z","timestamp":1788291704000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/16\/6\/2808\/509601\/Simultaneous-Transdermal-Delivery-of-Buprenorphine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,5,9]]},"published-print":{"date-parts":[[2019,6,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00337","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,9]]}}}